SNGX Key Statistics, Chart & Performance
The current stock price of SNGX is 1.41 USD. In the past month the price decreased by -9.62%. In the past year, price decreased by -57.91%.
SNGX Latest News, Press Relases and Analysis
SNGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.53 | 409.49B | ||
| AMGN | AMGEN INC | 15.6 | 183.64B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 157.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.76 | 110.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.49 | 83.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 842.75 | 56.34B | ||
| INSM | INSMED INC | N/A | 44.18B | ||
| NTRA | NATERA INC | N/A | 32.46B | ||
| BIIB | BIOGEN INC | 10.87 | 26.68B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.41 | 21.97B | ||
| INCY | INCYTE CORP | 16.44 | 20.61B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.15B |
Related stock screener links
About SNGX
Company Profile
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 14 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Company Info
SOLIGENIX INC
29 Emmons Drive, Suite B-10
Princeton NEW JERSEY 08540 US
CEO: Christopher J. Schaber
Employees: 15
Phone: 16095388200
SOLIGENIX INC / SNGX FAQ
Can you describe the business of SOLIGENIX INC?
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 14 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Can you provide the latest stock price for SOLIGENIX INC?
The current stock price of SNGX is 1.41 USD. The price decreased by -1.4% in the last trading session.
Does SNGX stock pay dividends?
SNGX does not pay a dividend.
What is the ChartMill technical and fundamental rating of SNGX stock?
SNGX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for SNGX stock?
7 analysts have analysed SNGX and the average price target is 17.85 USD. This implies a price increase of 1165.96% is expected in the next year compared to the current price of 1.41.
What is the next earnings date for SNGX stock?
SOLIGENIX INC (SNGX) will report earnings on 2026-03-19, after the market close.
Can you provide the ownership details for SNGX stock?
You can find the ownership structure of SOLIGENIX INC (SNGX) on the Ownership tab.
SNGX Technical Analysis
SNGX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNGX. SNGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SNGX Financial Highlights
Over the last trailing twelve months SNGX reported a non-GAAP Earnings per Share(EPS) of -3.6. The EPS increased by 58.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -184.8% | ||
| ROE | -582.04% | ||
| Debt/Equity | 0 |
SNGX Forecast & Estimates
7 analysts have analysed SNGX and the average price target is 17.85 USD. This implies a price increase of 1165.96% is expected in the next year compared to the current price of 1.41.
For the next year, analysts expect an EPS growth of 53.09% and a revenue growth -100% for SNGX